Latest Insider Transactions at Syndax Pharmaceuticals Inc (SNDX)
This section provides a real-time view of insider transactions for Syndax Pharmaceuticals Inc (SNDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syndax Pharmaceuticals Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syndax Pharmaceuticals Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 18
2021
|
Fabrice Egros |
SELL
Open market or private sale
|
Direct |
13,609
-24.9%
|
$244,962
$18.65 P/Share
|
|
May 18
2021
|
Fabrice Egros |
BUY
Exercise of conversion of derivative security
|
Direct |
13,609
+17.65%
|
$95,263
$7.54 P/Share
|
|
Apr 26
2021
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+3.09%
|
$7,500
$15.46 P/Share
|
|
Apr 22
2021
|
Dennis Podlesak |
BUY
Open market or private purchase
|
Direct |
13,967
+24.39%
|
$195,538
$14.11 P/Share
|
|
Mar 01
2021
|
Fabrice Egros |
SELL
Open market or private sale
|
Direct |
10,241
-19.6%
|
$245,784
$24.31 P/Share
|
|
Mar 01
2021
|
Fabrice Egros |
BUY
Exercise of conversion of derivative security
|
Direct |
10,241
+14.13%
|
$61,446
$6.78 P/Share
|
|
Feb 08
2021
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
35,156
-42.11%
|
$703,120
$20.55 P/Share
|
|
Feb 08
2021
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
35,156
+29.63%
|
$246,092
$7.2 P/Share
|
|
Feb 03
2021
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Fabrice Egros |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
29,333
+50.0%
|
-
|
|
Feb 01
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-45.93%
|
$300,000
$20.19 P/Share
|
|
Feb 01
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+31.47%
|
$105,000
$7.2 P/Share
|
|
Jan 31
2021
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
1,771
+10.46%
|
$21,252
$12.0 P/Share
|
|
Jan 31
2021
|
Briggs Morrison |
BUY
Other acquisition or disposition
|
Direct |
1,771
+3.53%
|
$21,252
$12.0 P/Share
|
|
Dec 01
2020
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-45.93%
|
$330,000
$22.97 P/Share
|
|
Dec 01
2020
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+31.47%
|
$105,000
$7.2 P/Share
|
|
Nov 23
2020
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
29,972
-50.57%
|
$689,356
$23.27 P/Share
|
|
Nov 23
2020
|
Peter Ordentlich Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,972
+32.97%
|
$89,916
$3.08 P/Share
|
|
Nov 10
2020
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
17,466
-27.28%
|
$349,320
$20.06 P/Share
|
|
Nov 10
2020
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
17,466
+21.43%
|
$122,262
$7.2 P/Share
|
|
Nov 09
2020
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
62,938
-57.48%
|
$1,258,760
$20.04 P/Share
|
|
Nov 09
2020
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
62,938
+36.5%
|
$440,566
$7.2 P/Share
|
|
Nov 04
2020
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-84.99%
|
$2,000,000
$20.31 P/Share
|
|
Nov 04
2020
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+45.94%
|
$700,000
$7.2 P/Share
|
|
Jul 31
2020
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
2,665
+16.59%
|
$18,655
$7.97 P/Share
|
|
Jun 18
2018
|
Bvf Partners L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-68.94%
|
-
|